<DOC>
	<DOCNO>NCT01636960</DOCNO>
	<brief_summary>This study evaluate safety tolerability peginterferon alfa-2b ( PegIFN alfa-2b ) adjuvant treatment Japanese participant malignant melanoma definitive surgical resection include complete lymphadenectomy . Participants study initially receive PegIFN alfa-2b 8 week ( Induction Phase ) may continue receive PegIFN alfa-2b ( Maintenance Phase ) long experience clinical benefit ( Up 252 week ) . The primary hypothesis peginterferon alfa-2b administer weekly basis safe tolerate .</brief_summary>
	<brief_title>A Study Pegylated Interferon Alfa-2b ( MK-4031 ) Adjuvant Treatment Japanese Patients With Malignant Melanoma ( MK-4031-370 )</brief_title>
	<detailed_description>The study terminate 118 week study start , maintenance phase , due regulatory approval Japan .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Stage II III melanoma Primary melanoma completely excise Full lymphadenectomy within 84 day prior initiation study treatment Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Ocular melanoma melanoma mucous membrane Evidence distant nonregional lymph node metastases Intransit melanoma Previously treat interferon alpha/beta , chemotherapy , hormonal therapy , radiotherapy immunotherapy/vaccine melanoma</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>